About the Report
PD-(L)1/VEGF bispecifics are rapidly emerging as a major force in solid tumour oncology. This report explores the competitive landscape, leading assets, key clinical catalysts, and future indication opportunities, helping strategy, business development and competitive intelligence teams identify where the greatest opportunities may emerge next.
Key highlights include:
- China-to-Western data translation: – how are the impressive efficacy signals reported in China translating into Western patient populations?
- Visibility into design strategy – how are developers differentiating their products? Prioritizing the most developed assets in ivonescimab, pumitamig and SSGJ-707?
- A calendar of clinical catalysts — when are the key upcoming pivotal readouts, regulatory milestones and key competitive inflection points?
- Future indication expansion whitespace — which tumour types may represent the next major wave of registrational development for PD-(L)1/VEGF bispecifics?
- Strategic implications for competitive intelligence and portfolio teams — including where differentiation is most likely to emerge and how to position for future competitive shifts
You May Also Be Interested In…
Learn More About Consulting
What is Beacon Consulting?
- We are specialist life sciences market research and consultants, delivering tailored insights across the full drug development and commercialisation lifecycle.
- Combines scientific expertise, expert networks, and proprietary Beacon data to transform complex data into clear, strategic decisions.
- Provides fully customised research, spanning qualitative interviews, quantitative analysis, and desk research, aligned to your specific business objectives.
- Helps biopharma teams reduce risk, identify opportunities, and accelerate decision-making with actionable, decision-ready insights.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
